4502 and TAK Related Headlines
Go Back- Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
- New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
- Takeda's zasocitinib beats deucravacitinib in psoriasis study
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
- U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
- Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
- Takeda reports positive Phase 2/3 trial results for TAK-881 in immune disorder
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Takeda reports positive pediatric trial results for ENTYVIO ulcerative colitis treatment
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
- Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
- Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
- Takeda reports positive phase 3 results for zasocitinib psoriasis drug
- Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
- Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
- Innovent Biologics closes $11.4 billion partnership with Takeda
- Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
- Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
- Takeda reports 7-year dengue vaccine data showing sustained protection
- New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
- Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filin
- HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
- Innovent Biologics partners with Takeda in $11.4 billion cancer drug deal
- Takeda partners with Innovent for $1.2 billion oncology deal
- Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
- Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
- 20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
- Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
- Takeda names Rhonda Pacheco as U.S. business unit president
- Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
- TAKEDA presents positive oveporexton phase 3 results for narcolepsy type 1
- Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
- FDA approves expanded VONVENDI use for von Willebrand disease patients
- U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
- Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
- Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
- Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
4502 and TAK Related Press Releases
Go Back- Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
- New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
- U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
- Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
- Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
- Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
- Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
- Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
- Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
- Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
- New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
- Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filin
- HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
- Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
- Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
- 20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
- Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
- Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
- Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
- U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
- Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
- Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
- Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
4502 and TAK Related SEC Filings
Go Back- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 09
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 08
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: MARAGANORE JOHN
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: GILLIS STEVEN
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Reed Kimberly A.
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Iijima Masami
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: BROUSSARD BRUCE D
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kimura Koichiro
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Stoffels Paulus
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Miyabashira Asuka
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Tsusaka Miki
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furuta Milano
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Smoter Jennifer Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Platford Giles Richard
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ibrahim Ramy Riad Ahmed
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Greenway Nicola Deidre Petal
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Farajallah Awny Samaan Botros
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pignagnoli Agosti Marcello
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pacheco Rhonda Janice
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furney Natalie Anne Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Shannon Elaine Mary
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ricci Gabriele
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Bitetti Teresa Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Duprey Lauren Rusckowski
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kim Julie So-Young
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Plump Andrew Stewart
- Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Stoffels Paulus
- Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: BROUSSARD BRUCE D
- Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Kimura Koichiro
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 29
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 26
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
- Form IRANNOTICE TAKEDA PHARMACEUTICAL
- Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 01
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form SD TAKEDA PHARMACEUTICAL
- Form 6-K TAKEDA PHARMACEUTICAL For: May 19
- Form 6-K TAKEDA PHARMACEUTICAL For: May 13
- Form 6-K TAKEDA PHARMACEUTICAL For: May 13
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Smoter Jennifer Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Platford Giles Richard
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Furuta Milano
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Kim Julie So-Young
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Bitetti Teresa Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Ricci Gabriele
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Duprey Lauren Rusckowski
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Pignagnoli Agosti Marcello
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Plump Andrew Stewart
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Weber Christophe Pierre
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Greenway Nicola Deidre Petal
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Farajallah Awny Samaan Botros
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Ibrahim Ramy Riad Ahmed
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 26
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 25
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Kim Julie So-Young
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Bitetti Teresa Marie
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Furney Natalie Anne Marie
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Higashi Emiko
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: FUJIMORI YOSHIAKI
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Pignagnoli Agosti Marcello
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Miyabashira Asuka
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Ricci Gabriele
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Orsinger Michel Bruno
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Pacheco Rhonda Janice
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Reed Kimberly A.
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Shannon Elaine Mary
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: BUTEL JEAN LUC
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Furuta Milano
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Tsusaka Miki
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Weber Christophe Pierre
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Platford Giles Richard
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: MARAGANORE JOHN
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: GILLIS STEVEN
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: CLARK IAN T
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Plump Andrew Stewart
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Hatsukawa Koji
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Iijima Masami
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Duprey Lauren Rusckowski
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 02
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 10
- Form 6-K TAKEDA PHARMACEUTICAL For: Jan 29
- Form 6-K TAKEDA PHARMACEUTICAL For: Dec 18
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- Form 6-K TAKEDA PHARMACEUTICAL For: Dec 08
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
- Form 6-K TAKEDA PHARMACEUTICAL For: Nov 28
- Form 13F-HR TAKEDA PHARMACEUTICAL For: Sep 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 01
- Form 6-K TAKEDA PHARMACEUTICAL For: Sep 25
- Form 6-K TAKEDA PHARMACEUTICAL For: Sep 08
- Form N-PX TAKEDA PHARMACEUTICAL For: Aug 20
- Form 13F-HR TAKEDA PHARMACEUTICAL For: Jun 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 31
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 14
